STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more

STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cup of stimulation. Our choice today is pumpkin spice, which remains a seasonal favorite. Of course, you are invited to join us. For the full experience, we are still hawking replicas — take a look. Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. … The U.S. Food and Drug Administration approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the company has said could become its top-selling product ever, STAT says. The approval for the drug, known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its Genentech subsidiary, though in recent years it has fallen behind rivals in oncology. Analysts broadly see giredestrant becoming a multibillion-dollar blockbuster if Roche wins approval in other forms of breast cancer. New results from a closely watched clinical trial showed that weight loss drugs are effective for children as young as 6, though some doctors say they are concerned about the prospect of prescribing these medications to such young patients, The New York Times writes. The study, presented at the medical conference Obesity Week, examined children ages 6 to 11 who were taking semaglutide, the compound in Ozempic and Wegovy. Most children in the trial had severe obesity, meaning they had a body mass index of 35 or higher. After 68 weeks, nearly 40% of those who took the drug no longer had obesity, compared with none of the patients on a placebo. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe

Original Source

Read the full article at Statnews →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.